NEWARK, NJ -- Mark Jay Zucker, MD, JD, FACC, FACP, director of the Heart Failure Treatment and Transplant Program at Newark Beth Israel Medical Center, was voted president-elect of the New Jersey Chapter of the American College of Cardiology. His one-year term runs through 2005, with his tenure as president beginning in January 2006. An NJACC council member since 1992, Dr. Zucker serves as the Chapter's representative to Medicare. Most recently, he has been active on behalf of Chapter members in the resolution process surrounding recoupment of cardiac catheterization claims by Horizon BCBS of New Jersey.
A resident of Short Hills, Dr. Zucker has been involved with heart transplantation since 1987. After completing his cardiology fellowship at Northwestern University, he joined the faculty at Loyola University Medical Center as one of four attending transplant cardiologists. In September of 1989, Dr. Zucker relocated to New Jersey to become the Director of Cardiac Transplantation at Newark Beth Israel Medical Center.
In its fifteenth year under the leadership of Dr. Zucker, the Heart Failure Treatment and Transplant Program at Newark Beth Israel reached a milestone with 42 heart transplants in calendar year 2004, ranking it among the top ten programs in the country. The program's results rival those at major nationally recognized centers with a one-year survival rate over the past few years in excess of 90 percent and a three-year survival rate of 80 percent.
One element that sets the program apart from others is the unprecedented opportunity for patients to participate in the latest research and clinical drug trial studies, due in large part to Dr. Zucker's direction. He has been a principal investigator in over 20 pharmaceutical or device manufacturer-sponsored trials, an author of over 40 papers, abstracts, and book chapters, and a collaborating investigator in the Jarvik total artificial heart trial, the Thoratec Heartmate trials, and most recently the MicroMed DeBakey axial flow pump trial. Just last month, a 35-year old mother and patient of Dr. Zucker's with end-stage heart failure was the first individual in the Northeast U.S. to return home after receiving a biventricular support assist device (VAD). This device allowed her to live in her own home and experience a vastly improved quality of life while she continued with treatment. The patient subsequently received a heart transplant.
During his career, Dr. Zucker has been responsible for the pre-operative evaluation, post-operative care and immunosuppressive management of over 550 heart and 35 lung transplant recipients. Instrumental in developing New Jersey's first adult extracorporeal membrane oxygenation (ECMO) program, he has worked collaboratively with the pediatric cardiologists as one of two adult cardiologists at Newark Beth Israel's Center for Adults with Congenital Heart Disease. Through his affiliation with the Mount Sinai School of Medicine, as an associate clinical professor of medicine, he continues his commitment to academia and research.
In addition to his involvement with the American College of Cardiology, Dr. Zucker sits on the Board of Directors for the New Jersey Organ & Tissue Sharing Network and the Transplant Society of New Jersey. He is a member of the International Society for Heart and Lung Transplantation and a fellow of the American College of Chest Physicians and of the American College of Physicians.
Dr. Zucker earned his law degree from Loyola University School of Law in Chicago and is licensed to practice law in New York, New Jersey and Illinois.
An affiliate of the Saint Barnabas Health Care System, Newark Beth Israel is one of only 80 facilities in the United States to provide a full range of cardiac services including diagnostic cardiology, highly specialized cardiac surgery and the latest treatments for heart failure. Minimally invasive coronary artery bypass graft, beating heart surgery, valve surgery, robotic surgery and transmyocardial revascularization are among the surgical options available to adult candidates. Advanced heart failure treatment includes heart transplantation and mechanical support devices. An Adult Congenital Heart Disease Program, integrative cardiac medicine and clinical trial-research program complete the offerings.
Newark Beth Israel Medical Center is a 671-bed tertiary care teaching hospital with specialized services including heart and kidney transplantation, adult and pediatric cardiac surgery, hematology/ oncology, general and vascular surgery, behavioral health services, and maternal/child care. Newark Beth Israel is home to Children's Hospital of New Jersey.
Date: January 17, 2005
[ top ]